Global Finance News
07 Dec 2025, 18:46
Zoetis Wins Health Canada Approval for Portela, a Long-Acting Osteoarthritis Pain Treatment for Cats
Zoetis announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to relieve osteoarthritis pain in cats for up to three months with a single injection. Portela targets nerve growth factor (NGF), a key driver of OA pain, and has shown strong effectiveness and good tolerability in a nine-month European field study, including in cats with early-stage kidney disease.
Already approved in the EU, Portela is expected to become commercially available in Canada and Europe in 2026. The treatment offers a long-acting alternative for cats that are difficult to medicate regularly, addressing a major unmet need given that OA is common but often underdiagnosed—only 18% of affected cats receive a formal OA pain diagnosis.
Portela joins Zoetis’ expanding feline pain-management portfolio alongside Solensia, leveraging a unique NGF-binding mechanism to extend duration of relief. The product is administered subcutaneously every three months and is not recommended for use in breeding, pregnant, lactating cats, or cats under 12 months of age.
Zoetis highlighted the approval as part of its broader innovation strategy within companion-animal medicine.
Zoetis announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to relieve osteoarthritis pain in cats for up to three months with a single injection. Portela targets nerve growth factor (NGF), a key driver of OA pain, and has shown strong effectiveness and good tolerability in a nine-month European field study, including in cats with early-stage kidney disease.
Already approved in the EU, Portela is expected to become commercially available in Canada and Europe in 2026. The treatment offers a long-acting alternative for cats that are difficult to medicate regularly, addressing a major unmet need given that OA is common but often underdiagnosed—only 18% of affected cats receive a formal OA pain diagnosis.
Portela joins Zoetis’ expanding feline pain-management portfolio alongside Solensia, leveraging a unique NGF-binding mechanism to extend duration of relief. The product is administered subcutaneously every three months and is not recommended for use in breeding, pregnant, lactating cats, or cats under 12 months of age.
Zoetis highlighted the approval as part of its broader innovation strategy within companion-animal medicine.